- Previous Close
209.79 - Open
210.07 - Bid 198.67 x 800
- Ask --
- Day's Range
205.35 - 210.13 - 52 Week Range
196.80 - 281.70 - Volume
1,967,194 - Avg. Volume
4,375,203 - Market Cap (intraday)
147.275B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
38.91 - EPS (TTM)
5.29 - Earnings Date Apr 22, 2025
- Forward Dividend & Yield 1.28 (0.62%)
- Ex-Dividend Date Mar 28, 2025
- 1y Target Est
265.19
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.
www.danaher.com61,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DHR
View MorePerformance Overview: DHR
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DHR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DHR
View MoreValuation Measures
Market Cap
147.28B
Enterprise Value
162.34B
Trailing P/E
38.91
Forward P/E
27.03
PEG Ratio (5yr expected)
2.05
Price/Sales (ttm)
6.36
Price/Book (mrq)
2.97
Enterprise Value/Revenue
6.80
Enterprise Value/EBITDA
22.31
Financial Highlights
Profitability and Income Statement
Profit Margin
16.33%
Return on Assets (ttm)
3.98%
Return on Equity (ttm)
7.57%
Revenue (ttm)
23.88B
Net Income Avi to Common (ttm)
3.9B
Diluted EPS (ttm)
5.29
Balance Sheet and Cash Flow
Total Cash (mrq)
2.08B
Total Debt/Equity (mrq)
34.60%
Levered Free Cash Flow (ttm)
4.67B